Therefore, relevant variants of SLC31A1 will be pertinent pharmacogenetic biomarkers, which is much more actionable than gene expression, for platinum-based therapy in NSCLC patients especially in these subgroups. Here, SLC31A1 is linked to non-small cell lung carcinoma.